{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:35:45Z","timestamp":1792290945486,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ijrobp.2013.02.012","type":"journal-article","created":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T03:01:28Z","timestamp":1363748488000},"page":"504-509","source":"Crossref","is-referenced-by-count":115,"title":["Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival"],"prefix":"10.1016","volume":"86","clinical-trial-number":[{"clinical-trial-number":"nct00302159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00879437","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christopher A.","family":"Barker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2013.02.012_bib1","series-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumours Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision)","author":"CBTRUS","year":"2012"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib4","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib5","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in\u00a0vitro and in\u00a0vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib9","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/85.9.704","article-title":"Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials","volume":"85","author":"Curran","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0360-3016(97)00485-9","article-title":"Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06","volume":"40","author":"Scott","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib12","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","article-title":"Efficacy of anti-epileptic drugs in patients with gliomas and seizures","volume":"256","author":"van Breemen","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib14","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","article-title":"P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy","volume":"72","author":"Oberndorfer","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib16","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0013-9580.2004.00104.x","article-title":"The activity of antiepileptic drugs as histone deacetylase inhibitors","volume":"45","author":"Eyal","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"B J Neurosurg"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib19","doi-asserted-by":"crossref","first-page":"S697","DOI":"10.1016\/j.ijrobp.2008.06.600","article-title":"Valproic acid shows normal tissue protection in a rat spinal cord model","volume":"72","author":"Kornguth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib20","doi-asserted-by":"crossref","first-page":"S669","DOI":"10.1016\/j.ijrobp.2011.06.919","article-title":"Valproic Acid enhances radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells in\u00a0vivo and in\u00a0vitro","volume":"81","author":"Thotala","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.02.012_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijrobp.2005.12.002","article-title":"Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy","volume":"65","author":"Ruben","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T18:20:02Z","timestamp":1539800402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301613001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0360301613001806"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2013.02.012","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}